TY - STD TI - World Health Organization, Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed Feb 27 2015. UR - http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx ID - ref1 ER - TY - JOUR AU - Elbasha, E. H. 1. AU - Dasbach, E. J. AU - Insinga, R. P. PY - 2007 DA - 2007// TI - Model for assessing human papillomavirus vaccination strategies JO - Emerg Infect Dis VL - 13 UR - https://doi.org/10.3201/eid1301.060438 DO - 10.3201/eid1301.060438 ID - Elbasha2007 ER - TY - JOUR AU - Villa, L. L. AU - Costa, R. L. AU - Petta, C. A. AU - Andrade, R. P. AU - Ault, K. A. AU - Giuliano, A. R. PY - 2005 DA - 2005// TI - Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial JO - Lancet Oncol VL - 6 UR - https://doi.org/10.1016/S1470-2045(05)70101-7 DO - 10.1016/S1470-2045(05)70101-7 ID - Villa2005 ER - TY - JOUR AU - Garland, S. M. AU - Hernandez-Avila, M. AU - Wheeler, C. M. AU - Perez, G. AU - Harper, D. M. AU - Leodolter, S. PY - 2007 DA - 2007// TI - Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa061760 DO - 10.1056/NEJMoa061760 ID - Garland2007 ER - TY - JOUR PY - 2007 DA - 2007// TI - Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa061741 DO - 10.1056/NEJMoa061741 ID - ref5 ER - TY - JOUR AU - Ault, K. A. PY - 2007 DA - 2007// TI - Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials JO - Lancet VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60852-6 DO - 10.1016/S0140-6736(07)60852-6 ID - Ault2007 ER - TY - JOUR AU - Muñoz, N. AU - Manalastas, R. AU - Pitisuttithum, P. AU - Tresukosol, D. AU - Monsonego, J. AU - Ault, K. PY - 2009 DA - 2009// TI - Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial JO - Lancet VL - 373 UR - https://doi.org/10.1016/S0140-6736(09)60691-7 DO - 10.1016/S0140-6736(09)60691-7 ID - Muñoz2009 ER - TY - JOUR AU - Villa, L. L. AU - Costa, R. L. AU - Petta, C. A. AU - Andrade, R. P. AU - Paavonen, J. AU - Iversen, O. E. PY - 2006 DA - 2006// TI - High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up JO - Br J Cancer VL - 95 UR - https://doi.org/10.1038/sj.bjc.6603469 DO - 10.1038/sj.bjc.6603469 ID - Villa2006 ER - TY - JOUR AU - Kim, J. J. AU - Goldie, S. J. PY - 2009 DA - 2009// TI - Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States JO - BMJ VL - 339 UR - https://doi.org/10.1136/bmj.b3884 DO - 10.1136/bmj.b3884 ID - Kim2009 ER - TY - STD TI - Kim Y, Ahn J, Kim YJ, Park J, Kim J, Lee YJ, et al. Economic Evaluation of HPV Vaccination. National Evidence-based Healthcare Collaborating Agency, 2013. In Korean ID - ref10 ER - TY - JOUR AU - Sassi, F. PY - 2006 DA - 2006// TI - Calculating QALYs, comparing QALY and DALY calculations JO - Health Policy Plan VL - 21 UR - https://doi.org/10.1093/heapol/czl018 DO - 10.1093/heapol/czl018 ID - Sassi2006 ER - TY - JOUR AU - Whitehead, S. J. AU - Ali, S. PY - 2010 DA - 2010// TI - Health outcomes in economic evaluation: the QALY and utilities JO - Br Med Bull VL - 96 UR - https://doi.org/10.1093/bmb/ldq033 DO - 10.1093/bmb/ldq033 ID - Whitehead2010 ER - TY - JOUR AU - Kuppermann, M. AU - Melnikow, J. AU - Slee, C. AU - Tancredi, D. J. AU - Kulasingam, S. AU - Birch, S. PY - 2010 DA - 2010// TI - Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions JO - Gynecol Oncol VL - 118 UR - https://doi.org/10.1016/j.ygyno.2010.05.002 DO - 10.1016/j.ygyno.2010.05.002 ID - Kuppermann2010 ER - TY - JOUR AU - Howard, K. AU - Salkeld, G. AU - McCaffery, K. AU - Irwig, L. PY - 2008 DA - 2008// TI - HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? JO - Health Econ VL - 17 UR - https://doi.org/10.1002/hec.1278 DO - 10.1002/hec.1278 ID - Howard2008 ER - TY - JOUR AU - Melnikow, J. AU - Kuppermann, M. AU - Birch, S. AU - Chan, B. K. AU - Nuovo, J. PY - 2002 DA - 2002// TI - Management of the low-grade abnormal Pap smear: What are women's preferences? JO - J Fam Pract VL - 51 ID - Melnikow2002 ER - TY - JOUR AU - Mennini, F. S. AU - Panatto, D. AU - Marcellusi, A. AU - Cristoforoni, P. AU - Vincenzo, R. AU - Capua, E. PY - 2011 DA - 2011// TI - Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy JO - Clin Ther VL - 33 UR - https://doi.org/10.1016/j.clinthera.2011.06.012 DO - 10.1016/j.clinthera.2011.06.012 ID - Mennini2011 ER - TY - JOUR AU - Jewell, E. L. AU - Smrtka, M. AU - Broadwater, G. AU - Valea, F. AU - Davis, D. M. AU - Nolte, K. C. PY - 2011 DA - 2011// TI - Utility scores and treatment preferences for clinical early-stage cervical cancer JO - Value Health VL - 14 UR - https://doi.org/10.1016/j.jval.2010.11.017 DO - 10.1016/j.jval.2010.11.017 ID - Jewell2011 ER - TY - JOUR AU - Marcellusi, A. AU - Capone, A. AU - Favato, G. AU - Mennini, F. S. AU - Baio, G. AU - Haeussler, K. PY - 2015 DA - 2015// TI - Health utilities lost and risk facto+rs associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group JO - Clin Ther VL - 37 UR - https://doi.org/10.1016/j.clinthera.2014.11.002 DO - 10.1016/j.clinthera.2014.11.002 ID - Marcellusi2015 ER - TY - JOUR AU - Hadorn, D. C. PY - 1991 DA - 1991// TI - The role of public values in setting health care priorities JO - Soc Sci Med VL - 32 UR - https://doi.org/10.1016/0277-9536(91)90303-T DO - 10.1016/0277-9536(91)90303-T ID - Hadorn1991 ER - TY - JOUR AU - Bae, E. Y. PY - 2008 DA - 2008// TI - Guidelines for economic evaluation of pharmaceuticals in Korea JO - J Prev Med Public Health VL - 41 UR - https://doi.org/10.3961/jpmph.2008.41.2.80 DO - 10.3961/jpmph.2008.41.2.80 ID - Bae2008 ER - TY - JOUR AU - Dolan, P. AU - Olsen, J. A. AU - Menzel, P. AU - Richardson, J. PY - 2003 DA - 2003// TI - An inquiry into the different perspectives that can be used when eliciting preferences in health JO - Health Econ VL - 12 UR - https://doi.org/10.1002/hec.760 DO - 10.1002/hec.760 ID - Dolan2003 ER - TY - JOUR AU - Gafni, A. PY - 1994 DA - 1994// TI - The standard gamble method: what is being measured and how it is interpreted JO - Health Serv Res VL - 29 ID - Gafni1994 ER - TY - JOUR AU - Dolan, P. AU - Sutton, M. PY - 1997 DA - 1997// TI - Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values JO - Soc Sci Med VL - 44 UR - https://doi.org/10.1016/S0277-9536(96)00271-7 DO - 10.1016/S0277-9536(96)00271-7 ID - Dolan1997 ER - TY - JOUR AU - Salomon, J. A. AU - Murray, C. J. PY - 2004 DA - 2004// TI - A multi-method approach to measuring health-state valuations JO - Health Econ VL - 13 UR - https://doi.org/10.1002/hec.834 DO - 10.1002/hec.834 ID - Salomon2004 ER - TY - JOUR AU - Ustün, T. B. AU - Rehm, J. AU - Chatterji, S. AU - Saxena, S. AU - Trotter, R. AU - Room, R. PY - 1999 DA - 1999// TI - Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO/NIH Joint Project CAR Study Group JO - Lancet VL - 354 UR - https://doi.org/10.1016/S0140-6736(98)07507-2 DO - 10.1016/S0140-6736(98)07507-2 ID - Ustün1999 ER - TY - JOUR AU - Breetvelt, I. S. AU - Dam, F. S. PY - 1991 DA - 1991// TI - Underreporting by cancer patients: the case of response-shift JO - Soc Sci Med VL - 32 UR - https://doi.org/10.1016/0277-9536(91)90156-7 DO - 10.1016/0277-9536(91)90156-7 ID - Breetvelt1991 ER -